<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00463073</url>
  </required_header>
  <id_info>
    <org_study_id>CBI-GBM-01</org_study_id>
    <nct_id>NCT00463073</nct_id>
  </id_info>
  <brief_title>Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas</brief_title>
  <official_title>A Phase II Trial With Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas and Progression After Radiation Therapy and Temozolamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg Universitetshospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The
      activity is limited, with an approximately 15 % response rate and a progression-free survival
      of 3-5 months. Given the synergy between irinotecan and bevacizumab in colorectal cancer, and
      the high-level expression of vascular endothelial growth factor on malignant gliomas, one
      would expect synergy between bevacizumab and irinotecan against gliomas. In addition, 40-50 %
      of GBM have EGFR amplification/mutation making the EGFR an additional target. By combing
      cetuximab, with irinotecan and bevacizumab, one would expect further response, than
      irinotecan and bevacizumab alone. In addition, recurrent gliomas have an extremely poor
      prognosis, so innovative therapies are needed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">32</enrollment>
  <condition>Malignant Gliomas</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Histological verification of primary GBM

          -  Recurrence or progression after standard treatment (debulking surgery of possible,
             radiotherapy and temozolamide within last six months)

          -  Evidence of measurable recurrent progressive primary GBM (CT/MRI scan)

          -  PS 0-2 (ECOG scale)

          -  Age &gt; 18

          -  Life expectancy &gt; 3 month

          -  Normal organ function:

          -  Platelets &gt; 125 x 109/l

          -  Hemoglobin &gt;6,2 mmol/l

          -  Leukocytes &gt; 3 x 109/l

          -  ACN&gt; 1,5 x 109/l

          -  ASAT and/or ALAT &lt; 3 x upper normal limit

          -  Bilirubin &lt; 1,5 x upper normal limit

          -  Creatinine clearance &gt; 45 ml/min

          -  Creatinine &lt; 1,5 x upper normal limit

          -  APTT &lt; normal limit

          -  INR &lt; normal limit

          -  Cholesterol &lt; 7 mmol/l

          -  Fertile females must use oral contraceptive, IUD (intrauterine device) or
             preservatives. Fertile males must use preservatives.

        Exclusion criteria:

          -  Radiotherapy or chemotherapy within the last 4 weeks.

          -  Co-medication that may interfere with study results; e.g. immunosuppressive agents
             other than corticosteroids

          -  Prior EGFR- or VEGFR- based therapy.

          -  Any condition (medical, social, psychological), which would prevent adequate
             information and follow-up

          -  Any other active malignancy or previous malignancies within the last 5 years, except,
             adequately treated basal or squamous cell carcinoma of the skin, or carcinoma in situ.

          -  No hypercholesterolemia or hypertriglyceridemia (despite lipid-lowering therapy).

          -  Any significant cardiac disease (New York Heart Association Class II or greater),
             arrhythmia, congestive heart failure, acute myocardial infarction within 6 months or
             unstable angina pectoris.

          -  Clinically significant peripheral vascular disease

          -  Evidence of bleeding diathesis, coagulapathy or taking ASA, NSAIDs or clopidogrel

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to day 0, anticipation of need for major surgical procedure during the curse of
             the study

          -  Minor surgical procedures, fine needle aspirations or core biopsies within 7 days
             prior to day 0

          -  History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
             within 6 month prior to day 0

          -  History of known HIV, Hepatitis B and Hepatitis C negative

          -  Any ongoing infection, uncontrolled diabetes mellitus, serious non-healing wound,
             ulcer or bone fracture

          -  Pregnancy or breast feeding

          -  Requires therapeutic anti-coagulation

          -  Blood pressure &gt; 150/100 mmHG

          -  Grade 2 or greater proteinuria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrik Lassen, MD., PH.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Dept. of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2007</study_first_submitted>
  <study_first_submitted_qc>April 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2007</study_first_posted>
  <last_update_submitted>December 10, 2008</last_update_submitted>
  <last_update_submitted_qc>December 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2008</last_update_posted>
  <keyword>Progressive primary Glioblastoma multiforme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

